Percheron Therapeutics Management

Management Kriterienprüfungen 1/4

Percheron Therapeutics CEO ist James Garner , ernannt in Aug 2023, hat eine Amtszeit von 1.25 Jahren. Die jährliche Gesamtvergütung beträgt A$824.68K , bestehend aus 52.7% Gehalt und 47.3% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.13% der Aktien des Unternehmens, im Wert von A$101.75K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.3 Jahre bzw. 3.1 Jahre.

Wichtige Informationen

James Garner

Geschäftsführender

AU$824.7k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	52.7%
Amtszeit als Geschäftsführer	1.3yrs
Eigentum des Geschäftsführers	0.1%
Durchschnittliche Amtszeit des Managements	1.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.1yrs

Jüngste Management Updates

Recent updates

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Jun 03

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Nov 13

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

May 12

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Dec 23

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Jun 24

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Mar 11

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Nov 26

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von James Garner im Vergleich zu den Einnahmen von Percheron Therapeutics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	AU$825k	AU$434k	-AU$12m
Mar 31 2024	n/a	n/a	-AU$11m
Dec 31 2023	n/a	n/a	-AU$11m
Sep 30 2023	n/a	n/a	-AU$11m
Jun 30 2023	AU$34k	n/a	-AU$11m

Vergütung im Vergleich zum Markt: JamesDie Gesamtvergütung ($USD535.93K) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Australian ($USD297.98K).

Entschädigung vs. Einkommen: JamesDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

James Garner (51 yo)

1.3yrs

Amtszeit

AU$824,684

Vergütung

Dr. James Garner, MA, MBA, MBBS, BSC (Hons), MAICD, serves as Non-Executive Director at Percheron Therapeutics Limited (formerly known as Antisense Therapeutics Limited) since May 08, 2023 and has been its...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
James Garner	CEO, MD & Director	1.3yrs	AU$824.68k	0.13% A$ 101.7k
Deborah Ambrosini	Company Secretary & CFO	less than a year	AU$324.32k	keine Daten
Anthony Filippis	Chief Operating Officer	1.8yrs	AU$596.05k	keine Daten
Cathryn Clary	Chief Medical Advisor	no data	keine Daten	keine Daten

1.3yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: PERDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.3 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
James Garner	CEO, MD & Director	1.5yrs	AU$824.68k	0.13% A$ 101.7k
Ben Price	Independent Non-Executive Director	3.1yrs	AU$113.77k	0.094% A$ 74.0k
Charmaine Gittleson	Independent Non-Executive Chair	3.7yrs	AU$220.29k	0.069% A$ 54.3k

3.1yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrener Vorstand: PERDie Vorstandsmitglieder gelten als erfahren (3.1 Jahre durchschnittliche Amtszeit).

Percheron Therapeutics Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023

Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023

Less than half of directors are independent

Antisense Therapeutics Limited Announces Retirement of Mark Diamond as Chief Executive Officer

Antisense Therapeutics Limited, Annual General Meeting, Nov 17, 2022

Antisense Therapeutics Limited Announces Appointment of Anthony Filippis as Chief Commercial Officer

Recent updates

Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million.

New minor risk - Shareholder dilution

Consensus EPS estimates upgraded to AU$0.031 loss

Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million.

New major risk - Financial position

Consensus EPS estimates upgraded to AU$0.034 loss

Forecast to breakeven in 2027

Consensus revenue estimates decrease by 40%

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Consensus EPS estimates upgraded to AU$0.022 loss

Price target increased by 7.1% to AU$0.30

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023

Consensus revenue estimates increase by 71%

New minor risk - Financial data availability

New major risk - Financial position

New minor risk - Shareholder dilution

Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK

We're Not Very Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Rate

Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023

Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Antisense Therapeutics Limited Commences the Second Phase (Chronic Setting) of Its Program to Study the Effects of an Antisense Oligonucleotide (ASO) to CD49d (Mouse Equivalent of ATL1102) in a LGMDR2 Animal Model of Dysferlin Deficiency

Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMD

Antisense Therapeutics Limited Announces Clinical Trial Application Submit for ATL1102 Phase IIb DMD trial conduct in Europe

Less than half of directors are independent

Price target increased to AU$0.31

Antisense Therapeutics Limited Announces Retirement of Mark Diamond as Chief Executive Officer

Antisense Therapeutics Limited Initiates the Process with Contract Research Organisation Pharmaron

Antisense Therapeutics Limited, Annual General Meeting, Nov 17, 2022

Antisense Therapeutics Limited Announces Appointment of Anthony Filippis as Chief Commercial Officer

Price target increased to AU$0.31

Antisense Therapeutics Limited Announces Dosing Commenced in DMD Combination Therapy Study

Consensus forecasts updated

Antisense Therapeutics Limited Intends to Conduct Double-Blind, Placebo Controlled Six Month Dosing Trial of Atl1102 Followed by Six Month Open Label Phase

Full year 2022 earnings released: AU$0.009 loss per share (vs AU$0.015 loss in FY 2021)

We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely

Antisense Therapeutics Limited Announces Long COVID-19 Study Identifies Novel Blood Markers as Potential Diagnostic and Therapeutic Targets

Antisense Therapeutics Limited Announces Outcomes from Its Collaboration to Study the Neurological Aspects of Long COVID-19

Antisense Therapeutics Limited Announces ATL1102 DMD Clinical Trial Application Submitted in Europe

Antisense Therapeutics Limited Announces Results from First Study of Antisense to CD49d in Limb Girdle Muscular Dystrophy R2 Mouse Model

Antisense Therapeutics Limited Announces the Results from A First Study of Antisense to CD49d in A Limb Girdle Muscular Dystrophy R2 (LGMDR2) Mouse Model

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Price target increased to AU$0.58

Antisense Therapeutics Limited Announces Dosing Commenced in MCRI Collaboration Animal Study

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Price target increased to AU$0.60

Antisense Therapeutics Limited Announces New Data Supports ATL1102s Broader Clinical Potential

Forecast to breakeven in 2024

Price target increased to AU$0.54

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Antisense Therapeutics Limited Announces US FDA Feedback on Type C Meeting for ATL1102 in the US

Antisense Therapeutics Limited Announces Manufacture of ATL1102 clinical supplies for Phase IIb trial

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Antisense Therapeutics Limited Announces the Paediatric Investigation Plan for ATL1102 in DMD Submitted to European Medicines Agency

Antisense Therapeutics Limited Announces Executive Changes

New 90-day high: AU$0.21

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Antisense Therapeutics Limited, Annual General Meeting, Dec 18, 2020

Antisense Therapeutics Limited Announces Statistically Significant Improvement in Pul2.0 with Atl1102 Treatment in Non-Ambulant Boys with DMD Compared to A Matched Natural History Control

An unknown buyer acquired a 49% stake in Antisense Therapeutics Limited (ASX:ANP) from Opthea Limited (ASX:OPT) for AUD 0.34 million.

Antisense Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit